Mifepristone: Phase III discontinued

Corcept discontinued the double-blind, U.S. Phase III Study 14 after an interim analysis of 226 patients with psychotic depression by an independent DMC showed that once-daily 1,200 mg oral mifepristone was unlikely to meet the primary endpoint of a greater proportion of patients who achieve a >=50% reduction from baseline in BPRS PSS score at day 7 and sustained through day 56 vs. placebo. Patients received mifepristone or placebo for 7 days followed by an antidepressant. The trial was slated to enroll 450 patients. ...